(Q51296848)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Masatoshi Tanaka

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Ryoko Kuromatsu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Hiroaki Nagamatsu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Kenji Sakata

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Satoru Matsugaki

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Masahiko Kajiwara

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Kunitaka Fukuizumi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Nobuyoshi Tajiri

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Norito Matsukuma

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Terufumi Sakai

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Noriyuki Ono

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Yoichi Yano

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Hironori Koga

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Junichi Kurogi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Akio Takata

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Shuji Sumie

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Manabu Satani

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Shingo Yamada

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Takashi Niizeki

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Hajime Aino

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Hideki Iwamoto

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Takuji Torimura

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Michio Sata

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

9 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

108-114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

Global cancer statistics, 2002

17 February 2020

cites work

1 reference

Hepatocellular carcinoma: epidemiology, risk factors, and screening

21 January 2018

1 reference

Early hepatocellular carcinoma as an entity with a high rate of surgical cure

21 January 2018

1 reference

21 January 2018

Hepatocellular carcinoma

1 reference

Management of hepatocellular carcinoma

21 January 2018

1 reference

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Current strategy for staging and treatment: the BCLC update and future prospects.

21 January 2018

1 reference

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan

21 January 2018

1 reference

Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

21 January 2018

1 reference

Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).

21 January 2018

1 reference

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

21 January 2018

1 reference

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000342650

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147476%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference